Lunsekimig
ACT18301
Phase 2 small_molecule active
Quick answer
Lunsekimig for Asthma is a Phase 2 program (small_molecule) at Sanofi Pasteur with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sanofi Pasteur
- Indication
- Asthma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active